Table 1.
Baseline characteristics
| Clinic group (n=446) | Hybrid group (n=442) | Community group (n=427) | Total (N=1315) | ||
|---|---|---|---|---|---|
| Gender | |||||
| Men | 230 (52%) | 217 (49%) | 219 (51%) | 666 (51%) | |
| Women | 216 (48%) | 225 (51%) | 208 (49%) | 649 (49%) | |
| Age, years | |||||
| 18–29 | 150 (34%) | 179 (40%) | 158 (37%) | 487 (37%) | |
| 30–49 | 264 (59%) | 230 (52%) | 234 (55%) | 728 (55%) | |
| ≥50 | 32 (7%) | 33 (7%) | 35 (8%) | 100 (8%) | |
| Education | |||||
| Primary | 136/439 (31%) | 144/431 (33%) | 123/412 (30%) | 403/1282 (31%) | |
| Secondary | 289/439 (66%) | 275/431 (64%) | 272/412 (66%) | 836/1282 (65%) | |
| Tertiary | 14/439 (3%) | 12/431 (3%) | 17/412 (4%) | 43/1282 (3%) | |
| Employed | 177 (40%) | 190 (43%) | 176 (41%) | 543 (41%) | |
| Study household size | |||||
| 1 | 425 (95%) | 424 (96%) | 407 (95%) | 1256 (96%) | |
| 2 | 21 (5%) | 18 (4%) | 20 (5%) | 59 (4%) | |
| In relationship | 276 (62%) | 285 (64%) | 279 (65%) | 840 (64%) | |
| Number of current sexual partners | |||||
| 0 | 37/440 (8%) | 40/439 (9%) | 34/426 (8%) | 111/1305 (9%) | |
| 1 | 331/440 (75%) | 332/439 (76%) | 326/426 (77%) | 989/1305 (76%) | |
| ≥2 | 72/440 (16%) | 67/439 (15%) | 66/426 (15%) | 205/1305 (16%) | |
| Condom used at last sex | 108/439 (25%) | 94/435 (22%) | 93/422 (22%) | 295/1296 (23%) | |
| Circumcised if male | 54/230 (23%) | 43/217 (20%) | 47/219 (21%) | 144/666 (22%) | |
| Patient aware of nearby HIV clinic | 436 (98%) | 436/441 (99%) | 415 (97%) | 1287/1314 (98%) | |
| WHO stage | |||||
| Stage 1 | 395 (89%) | 399 (90%) | 382 (89%) | 1176 (89%) | |
| Stage 2 | 40 (9%) | 36 (8%) | 40 (9%) | 116 (9%) | |
| Stage 3 | 11 (2%) | 7 (2%) | 5 (1%) | 23 (2%) | |
| CD4 cell count, cells per μL | |||||
| 100–349 | 150 (34%) | 143 (32%) | 160 (37%) | 453 (34%) | |
| 350–499 | 106 (24%) | 107 (24%) | 110 (26%) | 323 (25%) | |
| ≥500 | 190 (43%) | 192 (43%) | 157 (37%) | 539 (41%) | |
| Creatinine, μmol/L | |||||
| <106 | 418 (94%) | 417 (94%) | 408 (96%) | 1243 (95%) | |
| 106–133 | 28 (6%) | 25 (6%) | 19 (4%) | 72 (5%) | |
| Dried blood spot viral load, copies per mL | |||||
| 20–999 | 89/404 (22%) | 96/404 (24%) | 79/396 (20%) | 264/1204 (22%) | |
| 1000–9999 | 156/404 (39%) | 145/404 (36%) | 175/396 (44%) | 476/1204 (40%) | |
| ≥10 000 | 159/404 (39%) | 163/404 (40%) | 142/396 (36%) | 464/1204 (39%) | |
Data are n (%). Data are for the modified intention-to-treat population.